Delcath's liver cancer drug gains FDA orphan-drug status

09/1/2009 | Reuters · Forbes

The FDA granted Delcath Systems' doxorubicin orphan-drug designation as a treatment for primary liver cancer. The company said it plans to further test doxorubicin with its Percutaneous Hepatic Perfusion drug-delivery technology.

View Full Article in:

Reuters · Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA